IPHA (Innate Pharma) Moat Score: 4/10 (As of Jun. 24, 2026)


IPHA Innate Pharma SA IPHA
41 GF Score
Price $1.90
GF Value $0.16
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Innate Pharma Moat Score?

Innate Pharma IPHA -0.05% 41 Moat Score is 4 as of Jun. 24, 2026. GuruFocus rates IPHA with a GF Score™ of 41/100 and a GF Value™ of $0.16 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 1,405 Biotechnology companies, Innate Pharma ranks better than 88.83% on this metric.

Innate Pharma has the Moat Score of 4, which implies that the company might have Narrow Moat - Discernible but modest moat.

Innate Pharma has Narrow Moat: Innate Pharma has valuable patents and a focus on innovative immunotherapies. However, it faces significant competition and regulatory challenges, limiting its moat to a modest level.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Innate Pharma might have Narrow Moat - Discernible but modest moat.

Innate Pharma  (NAS:IPHA) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Innate Pharma Moat Score Related Terms

IPHA vs VRTX, REGN, ALNY: Moat Score Comparison

For the Biotechnology subindustry, Innate Pharma's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Innate Pharma Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Innate Pharma's Moat Score distribution charts can be found below:

* The bar in red indicates where Innate Pharma's Moat Score falls into.


IPHA
41GF Score
Innate Pharma SA IPHA
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 4 mean?
Innate Pharma (IPHA) has a Moat Score of 4 as of Jun. 24, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Innate Pharma ranks #157 out of 1405 companies in the Biotechnology industry, placing it in the top 11.2%.
Is Innate Pharma's Moat Score too high?
Innate Pharma's current Moat Score is 4. The Biotechnology industry median Moat Score is 2.00. Innate Pharma's value of 4 is 100% above this industry median. Based on the distribution chart, Innate Pharma ranks #157 out of 1405 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Innate Pharma has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Innate Pharma's Moat Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Innate Pharma ranks #157 out of 1405 companies for Moat Score. This places Innate Pharma in the top 11% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Innate Pharma's value of 4 is 100% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,405 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Innate Pharma's current Moat Score of 4 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Innate Pharma's current Moat Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Innate Pharma stock overvalued right now?
Based on GuruFocus' analysis, Innate Pharma (IPHA) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.16, compared to a current price of $1.90 — trading 1086.9% above its estimated fair value. The current Moat Score is 4 and 100% above the Biotechnology industry median of 2.00. Innate Pharma's overall GF Score™ is 41/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Innate Pharma (IPHA), the current Moat Score is 4 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Innate Pharma (IPHA) Overvalued in 2026?

Based on GuruFocus' analysis, Innate Pharma stock appears to be overvalued. The current stock price of $1.90 is trading 1086.9% above its estimated GF Value™ of $0.16. GuruFocus considers Innate Pharma to be Significantly Overvalued.

Key valuation signals for IPHA:

  • Moat Score: 4
  • GF Value™: $0.16 vs. price of $1.90 (1086.9% above fair value)
  • GF Score™: 41/100 with 7 warning signs
  • Industry Position: 100% above the Biotechnology median (#157 of 1405)

No single metric tells the full story. See the IPHA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Innate Pharma Business Description

Address 117, Avenue de Luminy, Marseille, FRA, 13009
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.
41GF Score

Get the complete analysis for IPHA

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.90
Price
$0.16
GF Value